Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. 2012

Latif A Wafa, and Helen Cheng, and Nathan Plaa, and Fariba Ghaidi, and Takahiro Fukumoto, and Ladan Fazli, and Martin E Gleave, and Michael E Cox, and Paul S Rennie
Department of Urologic Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.

The androgen receptor (AR) plays a central role in prostate cancer progression to the castration-resistant (CR) lethal state. L-Dopa decarboxylase (DDC) is an AR coactivator that increases in expression with disease progression and is coexpressed with the receptor in prostate adenocarcinoma cells, where it may enhance AR activity. Here, we hypothesize that the DDC enzymatic inhibitor, carbidopa, can suppress DDC-coactivation of AR and retard prostate tumor growth. Treating LNCaP prostate cancer cells with carbidopa in transcriptional assays suppressed the enhanced AR transactivation seen with DDC overexpression and decreased prostate-specific antigen (PSA) mRNA levels. Carbidopa dose-dependently inhibited cell growth and decreased survival in LNCaP cell proliferation and apoptosis assays. The inhibitory effect of carbidopa on DDC-coactivation of AR and cell growth/survival was also observed in PC3 prostate cancer cells (stably expressing AR). In vivo studies demonstrated that serum PSA velocity and tumor growth rates elevated ∼2-fold in LNCaP xenografts, inducibly overexpressing DDC, were reverted to control levels with carbidopa administration. In castrated mice, treating LNCaP tumors, expressing endogenous DDC, with carbidopa delayed progression to the CR state from 6 to 10 weeks, while serum PSA and tumor growth decreased 4.3-fold and 5.4-fold, respectively. Our study is a first time demonstration that carbidopa can abrogate DDC-coactivation of AR in prostate cancer cells and tumors, decrease serum PSA, reduce tumor growth and delay CR progression. Since carbidopa is clinically approved, it may be readily used as a novel therapeutic strategy to suppress aberrant AR activity and delay prostate cancer progression.

UI MeSH Term Description Entries
D008297 Male Males
D009919 Orchiectomy The surgical removal of one or both testicles. Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011944 Receptors, Androgen Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA. Androgen Receptors,5 alpha-Dihydrotestosterone Receptor,Androgen Receptor,Dihydrotestosterone Receptors,Receptor, Testosterone,Receptors, Androgens,Receptors, Dihydrotestosterone,Receptors, Stanolone,Stanolone Receptor,Testosterone Receptor,5 alpha Dihydrotestosterone Receptor,Androgens Receptors,Receptor, 5 alpha-Dihydrotestosterone,Receptor, Androgen,Receptor, Stanolone,Stanolone Receptors,alpha-Dihydrotestosterone Receptor, 5
D002230 Carbidopa An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself. Methyldopahydrazine,Carbidopa, (R)-Isomer,Carbidopa, (S)-Isomer,Lodosin,Lodosyn,MK-485,MK-486,MK 485,MK 486,MK485,MK486
D004296 Dopa Decarboxylase One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of DOPA to DOPAMINE. It is of clinical importance in the treatment of Parkinson's disease. Decarboxylase, Dopa
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Latif A Wafa, and Helen Cheng, and Nathan Plaa, and Fariba Ghaidi, and Takahiro Fukumoto, and Ladan Fazli, and Martin E Gleave, and Michael E Cox, and Paul S Rennie
November 2011, The Prostate,
Latif A Wafa, and Helen Cheng, and Nathan Plaa, and Fariba Ghaidi, and Takahiro Fukumoto, and Ladan Fazli, and Martin E Gleave, and Michael E Cox, and Paul S Rennie
July 1991, The International journal of neuroscience,
Latif A Wafa, and Helen Cheng, and Nathan Plaa, and Fariba Ghaidi, and Takahiro Fukumoto, and Ladan Fazli, and Martin E Gleave, and Michael E Cox, and Paul S Rennie
January 2007, Journal of andrology,
Latif A Wafa, and Helen Cheng, and Nathan Plaa, and Fariba Ghaidi, and Takahiro Fukumoto, and Ladan Fazli, and Martin E Gleave, and Michael E Cox, and Paul S Rennie
January 1995, Annals of neurology,
Latif A Wafa, and Helen Cheng, and Nathan Plaa, and Fariba Ghaidi, and Takahiro Fukumoto, and Ladan Fazli, and Martin E Gleave, and Michael E Cox, and Paul S Rennie
May 1979, Wiener klinische Wochenschrift,
Latif A Wafa, and Helen Cheng, and Nathan Plaa, and Fariba Ghaidi, and Takahiro Fukumoto, and Ladan Fazli, and Martin E Gleave, and Michael E Cox, and Paul S Rennie
January 2017, PloS one,
Latif A Wafa, and Helen Cheng, and Nathan Plaa, and Fariba Ghaidi, and Takahiro Fukumoto, and Ladan Fazli, and Martin E Gleave, and Michael E Cox, and Paul S Rennie
November 1942, The Journal of physiology,
Latif A Wafa, and Helen Cheng, and Nathan Plaa, and Fariba Ghaidi, and Takahiro Fukumoto, and Ladan Fazli, and Martin E Gleave, and Michael E Cox, and Paul S Rennie
November 2006, Cancer research,
Latif A Wafa, and Helen Cheng, and Nathan Plaa, and Fariba Ghaidi, and Takahiro Fukumoto, and Ladan Fazli, and Martin E Gleave, and Michael E Cox, and Paul S Rennie
December 2005, The Prostate,
Latif A Wafa, and Helen Cheng, and Nathan Plaa, and Fariba Ghaidi, and Takahiro Fukumoto, and Ladan Fazli, and Martin E Gleave, and Michael E Cox, and Paul S Rennie
February 2004, The Journal of biological chemistry,
Copied contents to your clipboard!